• Home
  •  
    Regions
    • Europe
    • UK & Ireland
    • DACH
    • Nordic
    • France
    • Southern Europe
    • Benelux
    • CEE
    • Asia
  •  
    Deals
    • Buyouts
    • Venture
    • Exits
    • Refinancings
    • Build-up
    • Turnaround
    • Secondaries
    • Advanced deals search
  •  
    Funds
    • Buyout
    • Venture
    • Mezzanine
    • Debt
    • Funds-of-funds
    • Secondaries
    • Fundraising pipelines
    • Advanced funds search
  •  
    GPs & LPs
    • GP profiles
    • LP profiles
    • GP news
    • LP news
    • Sponsors search
    • LPs search
  •  
    Secondaries
    • Deals
    • Funds
    • News
    • Analysis
  •  
    People
    • People moves
    • Analysis
    • In Profile
    • Q&A
    • Videos
    • Comment
  •  
    Analysis
    • In Profile
    • Fundraising
    • Q&A
    • Comment
    • Videos
    • Podcast
    • Reports
    • Data Snapshots
  •  
    Unquote Data
    • Deals search
    • Exits search
    • Funds search
    • Sponsors search
    • Advisers search
    • LPs search
    • League tables
    • Reports
  • Sign in
  • Sign in
    • You are currently accessing unquote.com via your Enterprise account.

      If you already have an account please use the link below to sign in.

      If you have any problems with your access or would like to request an individual access account please contact our customer service team.

      Phone: +44 (0)203 741 1137

      Email: Georgina.Lawson@acuris.com

      • Sign in
     
      • Newsletters
      • Account details
      • Contact support
      • Sign out
     
  • Follow us
    • Twitter
    • LinkedIn
  • Free Trial
  • Subscribe
Unquote
Unquote
  • Home
  • Regions
  • Deals
  • Funds
  • GPs & LPs
  • Secondaries
  • People
  • Analysis
  • Unquote Data
  • You are currently accessing unquote.com via your Enterprise account.

    If you already have an account please use the link below to sign in.

    If you have any problems with your access or would like to request an individual access account please contact our customer service team.

    Phone: +44 (0)203 741 1137

    Email: Georgina.Lawson@acuris.com

    • Sign in
 
    • Newsletters
    • Account details
    • Contact support
    • Sign out
 
Unquote
  • Expansion

LSP, Andera et al. invest €116m in AM-Pharma

  • Francesca Veronesi
  • Francesca Veronesi
  • 16 July 2019
  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  

New investors LSP and Andera Partners have joined existing backers to inject €116m into Netherlands-based AM-Pharma, a clinical-stage biopharmaceutical company.

Existing investors Forbion, Ysios Capital, Kurma Partners, ID Invest Partners, BB Pureos Bioventures and Gilde Healthcare also took part in the round.

Proceeds will be used for the 1,400-patient international pivotal phase-III trial of recombinant human alkaline phosphatase (recAP) in patients with sepsis-associated acute kidney injury (AKI).

AM-Pharma

  • DEAL:

    Early-stage

  • VALUE:

    €116m

  • LOCATION:

    Bunnik

  • SECTOR:

    Healthcare

  • FOUNDED:

    2001

The company is backed by venture capital funds and corporate venture funds, and has raised €195m in equity and debt to date, according to a statement.

Previous funding
AM-Pharma completed a first financing round in 2001, gathering a total of €640,000 from management, private investors and BioPartner Startup Ventures, a venture fund supported by the Dutch Ministry of Economic Affairs.

Inventages and ABN Amro Life Sciences Capital provided AM-Pharma with €6m and €3m respectively in 2005. Two years later, Forbion and Inventages contributed €2.5m to the biotech and in 2008 injected €7m. At the time, AM-Pharma was making preparations for a potential IPO, and Forbion owned a large minority stake in the company, Unquote previously reported.

It then raised €29.2m from Ysios, KLS, BB Biotech, Forbion, Idinvest and Inventages in 2011. Ysios and KLS led the round, with the former contributing €4.5m in capital.

Three years later, Gilde and existing investors injected a further €12.2m funding.

Company
AM-Pharma is a clinical stage biopharmaceutical company developing treatment for AKI with its drug recAP. AKI has a high mortality rate and no approved pharmacological treatments. The most prominent cause of AKI, which affects millions of patients worldwide, is sepsis.

Founded in 2001, the business is based in Bunnik.

People
AM-Pharma
– Erik van den Berg (CEO).  
LSP – Martijn Kleijwegt (managing partner).
Andera Partners – Raphaël Wisniewski (partner).  

  • Tweet  
  • Facebook  
  • LinkedIn  
  • Google plus  
  • Send to  
  • Topics
  • Expansion
  • Benelux
  • Healthcare
  • Netherlands
  • Life Science Partners
  • Andera Partners

More on Expansion

Wealth managers and financial advisers
Blackstone takes minority stake in Groupe Premium

Deal values French wealth manager at EUR 1.15bn after earlier full exit attempt saw Eurazeo target EUR 1.5bn

  • Expansion
  • 31 July 2023
Risk and compliance management services
e-Attestations aims to triple size with new Keensight backing

Keensight is investing in the risk management platform via its EUR 1bn fifth fund, which closed in 2019

  • Expansion
  • 25 July 2023
Bolt-ons and buy-and-build platforms
The Bolt-Ons Digest - 3 July 2023

Unquote’s selection of the latest add-ons with Palatine's Anthesis, Nordic Capital's Regnology, Waterland's Janssen and more

  • Expansion
  • 03 July 2023
Valentina Vitali of Limerston Capital
GP Profile: Limerston Capital anticipates higher volume but more complex M&A as market steadies

UK-based GP is seeing dealflow driven by carve-outs and buy-and-build in a market where organic multiple arbitrage is no longer a given

  • GPs
  • 07 June 2023

Latest News

Fund closes in US dollars
  • Funds
Stonehage Fleming raises USD 130m for largest fund to date, eyes 2024 programme

Multi-family office has seen strong appetite, with investor base growing since 2016 to more than 90 family offices, Meiping Yap told Unquote

  • 05 September 2023
Clinical trials and biotechnology
  • Buyouts
Permira to take Ergomed private for GBP 703m

Sponsor deploys Permira VIII to ride new wave of take-privates; Blackstone commits GBP 200m in financing for UK-based CRO

  • 04 September 2023
Public sector software
  • Exits
Partners Group to release IMs for Civica sale in mid-September

Sponsor acquired the public software group in July 2017 via the same-year vintage Partners Group Global Value 2017

  • 04 September 2023
EMEA Public to Private M&A
  • Investments
Change of mind: Sponsors take to de-listing their own assets

EQT and Cinven seen as bellweather for funds to reassess options for listed assets trading underwater

  • 04 September 2023
Back to Top
  • About Unquote
  • Advertise
  • Contacts
  • About Acuris
  • Terms of Use
  • Privacy Policy
  • Group Disclaimer
  • Twitter
  • LinkedIn

© Merger Market

© Mergermarket Limited, 10 Queen Street Place, London EC4R 1BE - Company registration number 03879547

Digital publisher of the year 2010 & 2013

Digital publisher of the year 2010 & 2013